GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (STU:ECX) » Definitions » Quick Ratio

Epigenomics AG (STU:ECX) Quick Ratio : 1.93 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Epigenomics AG's quick ratio for the quarter that ended in Jun. 2023 was 1.93.

Epigenomics AG has a quick ratio of 1.93. It generally indicates good short-term financial strength.

The historical rank and industry rank for Epigenomics AG's Quick Ratio or its related term are showing as below:

STU:ECX' s Quick Ratio Range Over the Past 10 Years
Min: 0.88   Med: 2.14   Max: 10.98
Current: 1.93

During the past 13 years, Epigenomics AG's highest Quick Ratio was 10.98. The lowest was 0.88. And the median was 2.14.

STU:ECX's Quick Ratio is ranked better than
50.64% of 235 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.9 vs STU:ECX: 1.93

Epigenomics AG Quick Ratio Historical Data

The historical data trend for Epigenomics AG's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Quick Ratio Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.66 3.26 2.19 10.98 2.12

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.82 3.83 2.12 1.21 1.93

Competitive Comparison of Epigenomics AG's Quick Ratio

For the Diagnostics & Research subindustry, Epigenomics AG's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Quick Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Quick Ratio falls into.



Epigenomics AG Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Epigenomics AG's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(10.815-0.061)/5.074
=2.12

Epigenomics AG's Quick Ratio for the quarter that ended in Jun. 2023 is calculated as

Quick Ratio (Q: Jun. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(4.157-0)/2.15
=1.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Epigenomics AG  (STU:ECX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Epigenomics AG Quick Ratio Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (STU:ECX) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.